[Statins and probiotics in the prevention of urologic diseases].
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, better known as statins, may be associated with reduced prostate cancer risk. Statins have been reported to demonstrate chemopreventive potentials in prostate cancer cell lines, but the association in observational studies has been inconclusive.Probiotics, defined as live microbial food supplements, have been tested for an impact on a variety of clinical conditions, e.g., urinary tract infections and calcium oxalate stone disease. Furthermore, oral administration of a lactic acid bacterium was effective against experimentally induced bladder tumors. Relationships between cancer and intake of probiotics have mainly been studied in bladder and colon cancer.
Fischer
C
C
Klinik für Urologie und Kinderurologie, Klinikum Bayreuth GmbH, Hohe Warte 8, 95445 Bayreuth, Germany. claus.fischer@hohe-warte-bayreuth.de
Altwein
J
J
D000818:Animals; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D019936:Probiotics / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control; D014545:Urinary Calculi / Q000517:prevention & control; D014570:Urologic Diseases / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors